Search Results for: FGFR3

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ADD1 adducin 1
  • Caspase-mediated cleavage of cytoskeletal proteins
  • XBP1(S) activates chaperone genes
  • Miscellaneous transport and binding events
Novel IDUA alpha-L-iduronidase
  • HS-GAG degradation
  • CS/DS degradation
  • MPS I - Hurler syndrome
  • Mucopolysaccharidosis type I (MPS1); Hurler-Scheie syndrome (MPS1HS); Hurler syndrome (MPS1H); Scheie syndrome (MPS1S)
Novel GMPS guanine monophosphate synthase
  • Purine ribonucleoside monophosphate biosynthesis
  • Glutamic acid
Novel GRK4 G protein-coupled receptor kinase 4
Novel IRF2BPL interferon regulatory factor 2 binding protein like
Novel STK32B serine/threonine kinase 32B
FGF2 fibroblast growth factor 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Sucralfate
  • Pentosan polysulfate
  • Sirolimus
  • Heparin
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • ABT-510
FGF1 fibroblast growth factor 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Amlexanox
  • Heparin
  • Sucrosofate
  • Formic acid
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • Naphthalene Trisulfonate
  • Pazopanib
  • 5-aminonaphthalene-2-sulfonic acid
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
FGF23 fibroblast growth factor 23
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR1c and Klotho ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Post-translational protein phosphorylation
  • Hypophosphatemic rickets; X-Linked dominant hypophosphatemia (XLH); Autosomal dominant hypophosphatemic rickets (ADHR); Autosomal recessive hypophosphatemic rickets (ARHR); Hereditary hypophophatemic rickets with hypercalciuria (HHRH)
FGF9 fibroblast growth factor 9
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Transcriptional regulation of testis differentiation
FGF4 fibroblast growth factor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Heparin
  • TP-508
STAT3 signal transducer and activator of transcription 3
  • Interleukin-6 signaling
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signalling to STAT3
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by Leptin
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Association of TriC/CCT with target proteins during biosynthesis
  • Transcriptional regulation of pluripotent stem cells
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Activates STAT3
  • PTK6 Activates STAT3
  • Interleukin-20 family signaling
  • MET activates STAT3
  • MET activates STAT3
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-37 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • ENMD-1198
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
  • Oral cancer
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
FGF18 fibroblast growth factor 18
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
FGF6 fibroblast growth factor 6
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • FGFR4 ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
FGF3 fibroblast growth factor 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Kaposi's sarcoma
STAT1 signal transducer and activator of transcription 1
  • Interleukin-6 signaling
  • ISG15 antiviral mechanism
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Regulation of RUNX2 expression and activity
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
  • IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
RPL8 ribosomal protein L8
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Peptide chain elongation
  • SRP-dependent cotranslational protein targeting to membrane
  • SRP-dependent cotranslational protein targeting to membrane
  • Viral mRNA Translation
  • Selenocysteine synthesis
  • Major pathway of rRNA processing in the nucleolus and cytosol
  • Formation of a pool of free 40S subunits
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • (S)-3-phenyllactic acid
  • Anisomycin
  • Puromycin
FGF7 fibroblast growth factor 7
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR2
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
RPS6KA3 ribosomal protein S6 kinase A3
  • ERK/MAPK targets
  • CREB phosphorylation
  • Senescence-Associated Secretory Phenotype (SASP)
  • Senescence-Associated Secretory Phenotype (SASP)
  • Recycling pathway of L1
  • CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
  • RSK activation
  • RSK activation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Acetylsalicylic acid
  • Fostamatinib
  • Non-syndromic X-linked mental retardation
  • Coffin-Lowry syndrome (CLS)

Page 1 out of 3 pages